Research advances of small molecule inhibitors in the treatment of mixed lineage leukemia
10.16438/j.0513-4870.2022-0236
- VernacularTitle:治疗混合谱系白血病的小分子抑制剂研究进展
- Author:
Meng-lan LUO
1
,
2
;
Yu-ting CHEN
3
;
Tong-chao LIU
3
;
Yong-mei CUI
1
;
Dan-qi CHEN
3
;
Bing XIONG
3
Author Information
1. College of Sciences, Shanghai University, Shanghai 200444, China
2. University of Chinese Academy of Sciences, Chinese Academy of Sciences Shanghai Institute of Materia Medica, Shanghai 201203, China
3. University of Chinese Academy of Sciences, Chinese Academy of Sciences Shanghai Institute of Materia Medica, Shanghai 201203, China
- Publication Type:Research Article
- Keywords:
mixed lineage leukemia;
mixed lineage leukemia fusion protein;
epigenetic regulator;
inhibitor
- From:
Acta Pharmaceutica Sinica
2022;57(8):2292-2312
- CountryChina
- Language:Chinese
-
Abstract:
Acute leukemia (AL) is a kind of malignant clonal disease of hematopoietic stem cells. Rearrangement of mixed lineage leukemia (MLL) gene can be observed in about 5%-10% of AL patients. Currently, AL patients with MLL-rearrangements (MLL-r) lack effective treatment and are usually associated with poor prognoses. Recent studies have shown that many epigenetic regulators are directly or indirectly involved in the occurrence and development of AL carrying MLL-r (MLL), which provides a biological basis for the use of epigenetic regulation strategies to treat MLL. In this review, we start from the epigenetic regulation mechanism of MLL, and select representative drug targets to briefly analyze the relationship between each target and MLL and summarize the development progress of their inhibitors, hoping to provide reference for the subsequent research and development of drugs for the treatment of MLL.
